| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/10/2005 | WO2005011632A1 Target-directed and enteric absorption-controlled liposome having sugar chain and cancer remedy and diagnostic containing the same |
| 02/10/2005 | WO2005011407A1 Antitumor composition |
| 02/10/2005 | WO2004094462A3 Methods of peptide preparation |
| 02/10/2005 | WO2004093856A3 Combination of a cox-2 inhibitor and an alkylating-type antineoplastic agent for treatment of neoplasia |
| 02/10/2005 | WO2004087652A3 Imidazotriazine compounds |
| 02/10/2005 | WO2004080933A3 Isolation of lutein from alfalfa |
| 02/10/2005 | WO2004054507A3 Indolizine compounds |
| 02/10/2005 | WO2004035032A3 Pharmaceutical formulations of camptothecine derivatives |
| 02/10/2005 | WO2003086175A8 Compositions and methods for the therapy and diagnosis of lung cancer |
| 02/10/2005 | WO2003050295A3 Assays and implements for determining and modulating hsp90 binding activity |
| 02/10/2005 | WO2002064626A3 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 02/10/2005 | US20050033414 Drug-eluting stent with multi-layer coatings |
| 02/10/2005 | US20050033066 Pkb-3564 substance with neovascularization inhibitory activity |
| 02/10/2005 | US20050033055 Edg receptor agonists |
| 02/10/2005 | US20050033034 Anti-t cell immunotoxin fusion protein and its therapeutic use |
| 02/10/2005 | US20050033028 Reducing immunogenicities of immunoglobulins by framework-patching |
| 02/10/2005 | US20050033026 Immunoconjugates for the treatment of tumours |
| 02/10/2005 | US20050033018 Receptors and membrane-associated proteins |
| 02/10/2005 | US20050033017 Nucleotide sequences coding receptor for advanced glycation endproducts (RAGE) for identifying modulators for treatment and prevention of cell proliferative and cardiovascular disorders |
| 02/10/2005 | US20050032978 Copolymer of isobutylene with carbamate groups which is curable |
| 02/10/2005 | US20050032899 Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination |
| 02/10/2005 | US20050032890 Aniline-derived ligands for the thyroid receptor |
| 02/10/2005 | US20050032874 Indole derivatives |
| 02/10/2005 | US20050032860 CBI analogs of CC-1065 and the duocarmycins |
| 02/10/2005 | US20050032851 E. g.,N-[[4-[2-(5-Methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]acetamide; side effect reduction; non-steroidal antiinflammatory agents; antiarthritic agents; analgesics; antipyretics; acylation of the corresponding sulfoamide by an anhydride a solvent and base |
| 02/10/2005 | US20050032839 Useful in therapy and treatment of diseases associated with a disregulated protein kinase activity like cancer; Aurora kinases |
| 02/10/2005 | US20050032832 Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents |
| 02/10/2005 | US20050032830 Ether substituted imidazopyridines |
| 02/10/2005 | US20050032828 E. g., 4-[3-Isopropyl-3-(2-mercapto-benzothiazol-6-yl)-ureido]-piperidine-1-carboxylic acid benzyl ester; metabolic diseases; management/treatment glucose/fatty acid pathway; cardiovascular disorders; congestive heart failure; angina pectoris; antidiabetic agent, anticarcinogenic agents; obesity |
| 02/10/2005 | US20050032826 Medical devices containing rapamycin analogs |
| 02/10/2005 | US20050032825 rapamaycin derivatives used as fungicides, anticarcinogenic agents, immunosuppressants or as coatings on drug eluting stents to prevent restenosis |
| 02/10/2005 | US20050032823 analgesics; antipyretics; antiinflammatory agents; antiarthritic agents |
| 02/10/2005 | US20050032817 Kinesin spindle protein (KSP) inhibitors, e.g., 3-benzyl-2-(1-{(4-bromobenzyl)[2-(dimethylamino)ethyl]amino}propyl)furo[2,3-d]pyrimidin-4(3H)-one; antiproliferative and -carcinogenic agents; side effects reduction; cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung |
| 02/10/2005 | US20050032816 N-oxide anthranylamide derivatives and their use as medicaments |
| 02/10/2005 | US20050032803 as modulators of receptor tyrosine kinases and cytoplasmic tyrosine and serine/threonine kinases; can bind both to active and also to non-active kinases and therefore influence the signal transduction |
| 02/10/2005 | US20050032802 Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents |
| 02/10/2005 | US20050032801 Compositions containing a ruthenium(III) complex and a heterocycle |
| 02/10/2005 | US20050032798 Diaryl ureas, which release urea compound when administered to patient, for example, 1-(4-chloro-3(trifluoromethyl)phenyl)-3-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)-2-oxo-(1,3,5-perhydrotriazapine); treatment of cancer, inflammation |
| 02/10/2005 | US20050032785 LIVER CANCER; ADMINISTERING TAUROLIDINE, direct contact a liver tissue by perfusion in situ, to increase caspase activity in a cell; monitoring the treatment |
| 02/10/2005 | US20050032779 enzyme inhibitors such as 2-[4-(4-Dimethylaminophenyl)piperazin-1-yl]4,5-dihydroimidazo[4,5,1-ij]quinolin-6-one, used for treating or preventing disorders in which poly/ADP-ribose/ polymerase is involved |
| 02/10/2005 | US20050032778 Therapeutically active thiophenepyrimidinone compounds and their use |
| 02/10/2005 | US20050032759 administering to humans synergystic mixtures of aromatase inhibitors and epidermal growth factor receptor antagonists as antitumor agents |
| 02/10/2005 | US20050032738 (E)-2'-deoxy-2'-fluoromethylidenecytidine, cytidine, vinblastine, or fluorouracil; leukemia |
| 02/10/2005 | US20050032736 Immunostimulatory nucleic acid molecules |
| 02/10/2005 | US20050032730 Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions |
| 02/10/2005 | US20050032727 Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways |
| 02/10/2005 | US20050032724 Multidrug Resistance Protein 1 (MRP1); mutagenesis |
| 02/10/2005 | US20050032723 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
| 02/10/2005 | US20050032715 Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds |
| 02/10/2005 | US20050032704 Neural thread proteins (NTP); antiproliferative agents |
| 02/10/2005 | US20050032699 Composition of a VEGF antagonist and an anti-proliferative agent |
| 02/10/2005 | US20050032693 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization |
| 02/10/2005 | US20050032692 Methods of inhibiting tumor cell proliferation |
| 02/10/2005 | US20050032686 administering to a manimal a therapeutically effective amount of ES-62 ( a glycoprotein) to treat an inflammatory disease: arthritis and chronic obstructive pulmonary disease |
| 02/10/2005 | US20050032216 Plasmid comprising antibody specific for cell surface membrane protein receptor (5T4) for use in tissue directed treatment of tumors; tissue targeted therapy |
| 02/10/2005 | US20050032214 Cell-specific expression/replication vector |
| 02/10/2005 | US20050032189 Novel protein derived from agkistrodon saxatilis emelianov and process preparing the same |
| 02/10/2005 | US20050032168 17 human secreted proteins |
| 02/10/2005 | US20050032134 Neoplasm-specific polypeptides and their uses |
| 02/10/2005 | US20050032133 Method of determining whether a patient afflicted with cancer can be treated by a therapeutic agent that targets the 17-1a antigen |
| 02/10/2005 | US20050032101 Methods for diagnosis and therapy of cancer and composition useful therein |
| 02/10/2005 | US20050032062 Methods for the assessment and prognosis of sarcoidosis |
| 02/10/2005 | US20050032058 Using aberrant homeobox gene expression in hematopoietic cells as diagnostic indicator of cell proliferfative disorders |
| 02/10/2005 | US20050031695 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen |
| 02/10/2005 | US20050031642 Clonal lentogenic oncolytic strain of Newcastle Disease Virus and hemaglutinin-neuraminidase (HN) gene |
| 02/10/2005 | US20050031627 Methods for preparing immunoconjugates |
| 02/10/2005 | US20050031619 Therapeutic compositions that alter the immune response |
| 02/10/2005 | US20050031613 CD 16 antigen; antibody produced by cell unresistant to lectin which recognizes sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through alpha -bond in a complex N-glycoside-linked sugar chain; signal transduction |
| 02/10/2005 | US20050031612 Cytotoxic t lymphocytes; human leukocyte antigen; non-hematopoietic cells; graft versus host disease |
| 02/10/2005 | US20050031594 Pharmaceutical composition for treatment of cancers |
| 02/10/2005 | US20050031577 Therapeutic polyesters and polyamides |
| 02/10/2005 | US20050031575 Block copolymers |
| 02/10/2005 | US20050031542 using carbocyanine dyes; photodynamic therapy; supplying to tumors |
| 02/10/2005 | US20050029705 Extrusion die |
| 02/10/2005 | DE3823105B4 Dolastatin 10, Verfahren zu seiner Gewinnung, und es enthaltende pharmazeutische Zusammensetzungen Dolastatin 10, process for its production, and pharmaceutical compositions containing it |
| 02/10/2005 | DE10297513T5 In vitro Herstellung von dendritischen Zellen aus CD14+ Monocyten In vitro production of dendritic cells from CD14 + monocytes |
| 02/10/2005 | CA2534461A1 An agent for preventing and/or treating hematologic malignancies |
| 02/10/2005 | CA2533918A1 Use of adcc-optimized antibodies for treating weak patients |
| 02/10/2005 | CA2533789A1 Epha2 t-cell epitope agonists and uses therefor |
| 02/10/2005 | CA2533600A1 Quantitative method for detecting yessotoxins in fish products based on the activation caused by the toxin in cellular phosphodiesterase and therapeutic usefulness of said activation |
| 02/10/2005 | CA2533474A1 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
| 02/10/2005 | CA2533297A1 Anti-vegf antibodies |
| 02/10/2005 | CA2533287A1 Compounds for modulating cell proliferation |
| 02/10/2005 | CA2532965A1 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| 02/10/2005 | CA2532251A1 Cci-779 lyophilized formulations |
| 02/10/2005 | CA2531294A1 2-methylene-19-nor-20(s)-25-methyl-1.alpha.-hydroxycalciferol and its uses |
| 02/10/2005 | CA2518951A1 Protein kinase inhibitors |
| 02/10/2005 | CA2518950A1 Indazole derivatives |
| 02/09/2005 | EP1505154A1 Vector with modified protease-dependent tropism |
| 02/09/2005 | EP1505075A1 Antibody to human insulin-like growth factor |
| 02/09/2005 | EP1504124A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions |
| 02/09/2005 | EP1504108A2 Viral vector |
| 02/09/2005 | EP1504107A1 Recombinant fowlpox virus |
| 02/09/2005 | EP1504035A2 Antibodies specific for human cd22 and their therapeutic and diagnostic uses |
| 02/09/2005 | EP1504027A2 Adipocyte complement related protein zacrp8 |
| 02/09/2005 | EP1504019A1 Platinum complexes having antitumor activity |
| 02/09/2005 | EP1504014A2 Process for preparation of cyclic prodrugs of pmea and pmpa |
| 02/09/2005 | EP1504010A1 Vitamin-mitomycin conjugates |
| 02/09/2005 | EP1503993A2 Compounds, methods and compositions |
| 02/09/2005 | EP1503991A1 Hexahydro-pyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and preparation methods thereof |